Drugs / ROSE-010
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT01056107 | Jan 2010 → Dec 2011 | irritable bowel syndrome | Mayo Clinic | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT06621017 | Sep 2024 → Feb 2025 | obesity disorder | Rose Pharma Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROSE-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06621017 ↗ |
| Modality | Peptide | “A glucagon-like peptide-1 (GLP-1) analogue.” NCT01056107 ↗ |
| Route | Subcutaneous | “ROSE-010 (30, 100, or 300 μg sc) or matching placebo was administered” PMID 22517769 ↗ Apr 2012 |